Scholarlink

Background <p>Circulating tumor DNA variations (∆ctDNA) were reported to be associated with treatment efficacy in metastatic colorectal cancer (mCRC). The present study evaluated ∆ctDNA according to first-line treatment intensity.</p> Methods <p>Patients from two prospective ctDNA collections were divided into <i>Group</i> ≤ <i>2 drugs</i> and <i>Group</i> <i>≥</i> <i>3 drugs</i>. ∆ctDNA were analysed from baseline to cycle 3 or 4 (C<sub>3-4</sub>) according to three predefined subgroups: ∆ctDNA ≥ 80%<sub>_ undetectable</sub>, ∆ctDNA ≥ 80%<sub>_ detectable</sub>, and ∆ctDNA &lt; 80%. Impact of ∆ctDNA on progression-free survival (PFS) and overall survival (OS) were analysed.</p> Results <p>Pretreatment ctDNA was detected in 129/152 (84.9%) of patients. A ∆ctDNA ≥ 80%<sub>_undetectable</sub> was more frequent in <i>Group</i> ≥ <i>3</i> than <i>≤</i> <i>2 drugs (</i>respectively 51.5% <i>vs</i>. 32.7%, <i>p</i> = 0.015). Patients with ∆ctDNA ≥ 80%<sub>_undetectable</sub> had longer survival than other ∆ctDNA subgroups, in <i>Group</i> ≥ <i>3 drugs</i> (mPFS 11.5 <i>vs</i> 7.8 <i>vs</i> 6.3 months, <i>p</i> = 0.02: mOS 30.2 <i>vs</i> 18.1 <i>vs</i> 16.4 month, <i>p</i> = 0.04) and in <i>Group</i> ≤ <i>2 drugs</i> (mPFS 8.4 <i>vs</i> 6.0 <i>vs</i> 5.3 months, <i>p</i> = 0.05; mOS 29.6 <i>vs</i> 14.6 <i>vs</i> 14.6 months, <i>p</i> = 0.007).</p> Discussion <p>Early ∆ctDNA are associated to treatment intensity in first line mCRC with a significant impact on prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年3月15日

查看全文
  • Adrien Grancher,
  • Ludivine Beaussire-Trouvay,
  • Virginie Vernon,
  • Marie Dutherage,
  • Valérie Blondin,
  • Caroline Elie,
  • Karine Bouhier-Leporrier,
  • Marie-Pierre Galais,
  • Tifenn Clabaut,
  • Anne-Laure Bignon,
  • Aurélie Parzy,
  • Alice Gangloff,
  • Lilian Schwarz,
  • Emilie Lévêque,
  • Jean-Christophe Sabourin,
  • Pierre Michel,
  • Nasrin Vasseur,
  • David Sefrioui,
  • André Gilibert,
  • Frédéric Di Fiore

摘要

Background

Circulating tumor DNA variations (∆ctDNA) were reported to be associated with treatment efficacy in metastatic colorectal cancer (mCRC). The present study evaluated ∆ctDNA according to first-line treatment intensity.

Methods

Patients from two prospective ctDNA collections were divided into Group ≤ 2 drugs and Group ≥ 3 drugs. ∆ctDNA were analysed from baseline to cycle 3 or 4 (C3-4) according to three predefined subgroups: ∆ctDNA ≥ 80%_ undetectable, ∆ctDNA ≥ 80%_ detectable, and ∆ctDNA < 80%. Impact of ∆ctDNA on progression-free survival (PFS) and overall survival (OS) were analysed.

Results

Pretreatment ctDNA was detected in 129/152 (84.9%) of patients. A ∆ctDNA ≥ 80%_undetectable was more frequent in Group ≥ 3 than ≤ 2 drugs (respectively 51.5% vs. 32.7%, p = 0.015). Patients with ∆ctDNA ≥ 80%_undetectable had longer survival than other ∆ctDNA subgroups, in Group ≥ 3 drugs (mPFS 11.5 vs 7.8 vs 6.3 months, p = 0.02: mOS 30.2 vs 18.1 vs 16.4 month, p = 0.04) and in Group ≤ 2 drugs (mPFS 8.4 vs 6.0 vs 5.3 months, p = 0.05; mOS 29.6 vs 14.6 vs 14.6 months, p = 0.007).

Discussion

Early ∆ctDNA are associated to treatment intensity in first line mCRC with a significant impact on prognosis.